Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Apr 24, 2018 • 9:00 AM EDT
Ligand to Report First Quarter 2018 Results on May 8th
Mar 30, 2018 • 9:00 AM EDT
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Mar 6, 2018 • 4:01 PM EST
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Mar 13, 2018 • 8:30am EDT
See all events
Mar 12, 2018 • 4:30pm EDT
Dana Point, California
Feb 21, 2018 • 4:30pm EDT
May 8, 2018 • 4:30pm EDT
$ALDX announces first patient enrolled in reproxalap Phase 3 clinical trial for allergic conjunctivitis https://t.co/XbhVLOgc1Q
$SAGE submits NDA for Brexanolone IV in the treatment of postpartum depression https://t.co/TDg1wqgPvb
$SYRS announces new preclinical data on Captisol-enabled SY-1365 showing potent anti-tumor activity in multiple mod… https://t.co/kTytckvWJc